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Abstract “Let’s Move!” is a comprehensive initiative, launched by the First Lady, Michelle
Obama, dedicates to solving problems of obesity, which is growing in child. The life behaviors
do affect obesity; however, the mechanistic insight in molecular level is still not clear. In this
study, by continually monitoring mouse body weight under chow and high fat western diets as
well as metabolic, physical activity and food intake behaviors assessed in a CLAMS Comprehensive Lab Animal Monitoring System, we demonstrated that the platelet-activating factor receptor (PTAFR) contributes to modification of life behaviors. PTAFR does not affect metabolism of
ingested dietary fat and carbohydrate in young animals; however, Ptafr ablation dramatically
increased weight gain without affecting adipose tissue accumulation. Ptafr/ mice possess
new habits that increased food intake and decreased movement. Our studies suggest that regulation of PTAFR activity may be a novel strategy to control obesity in children or young adults.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Obesity is a growing worldwide health problem that is associated with an increased risk of cardiovascular diseases, type
II diabetes as well as cancer, and is positively correlated with
the presence of inflammatory factors.1 This population is
becoming young and children obesity has been a serious
public health concern to be solved. Platelet-activating factor
(1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF) is a
potent autocoiddlocally signaling hormonedthat initiates
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and localizes acute inflammation.2 PAF initiates signaling
after engagement of a G-protein coupled receptor, the PAF
receptor (PTAFR), with exceedingly high affinity.3e5 PTAFR is
expressed by most cells of the innate immune and vascular
systems, but is absent on hepatocytes.6 PTAFR is unique in
recognizing PAF to the exclusion of other physiologic phospholipids, although a range of phospholipids generated by
unregulated oxidative truncation of polyunsaturated choline
phospholipids are PTAFR agonists and are biologically
active.7
Despite the widespread roles of PAF and PTAFR in cell
activation ex vivo, genetic ablation of Ptafr does not
interfere with birth or viability, nor even induce marked
changes to the inflammatory system in the absence of overt
stimulation.3,4 We employed Ptafr/ mice to assess
circulating PAF and PAF-like oxidized phospholipids in blood
of older animals,8 and noted that most of these aged mice
were significantly obese when compared to age-matched
wild type C57BL6 mice (WT) or Apoe null mice (data not
shown). This phenotype was found in both genders. Our
findings are identical to the recent studies which reported
that loss of PTAFR increases adiposity over time, although
the mechanism for this weight gain is not fully elucidated.9,10 In this study, we provide additional evidence and
mechanistic insights regarding the role of PTAFR in obesity.
We found young Ptafr null mice were “couch potatoes” that
ingested significantly more food and moved significantly
less frequently. We conclude PTAFR signaling contributes to
behavior control in early life through the dual actions of
enhanced movement and feeding suppression separate
from a metabolic role, implicating PTAFR signaling in
behavior modification.

Statistical analyses were performed using Prisim4 (GraphPad) software. One-way ANOVA (Bonferroni/Dunn) was
used to determine the differences among groups. Unpaired
t test was used to determine differences between groups.
Data are presented as the mean  SEM, with p < 0.05
considered significant.

Material and methods

Results and discussion

All procedures and manipulations of mice have been
approved by the Institutional Animal Care and Use Committee (IACUC) of The Cleveland Clinic in accordance with
the United States Public Health Service Policy on the Humane Care and Use of Animals, and the NIH Guide for the
Care and Use of Laboratory Animals. WT mice were purchased from Jackson Laboratories. Ptafr/ mice, which
have been back-crossed to the C57/BL6 mouse more than
10 times, were from Jeffery Travers (University of Indiana)
with permission of the strain’s originator Takao Shimizu
(University of Tokyo). Animals were identified by ear tags
and fed ad libitum with regular chow (CD, 8604 Teklad
Rodent Diet) with the calorie contributions from protein,
fat, and carbohydrate being 32%, 14% and 54%, respectively. Harlan TD.88137 “Western diets” (WD) was used to
accelerate gain of body weight and the calorie contributions from protein, fat, and carbohydrate were 15.2%, 42%
and 42.7%. TD.88137 also includes 0.2% cholesterol by
weight. Mice were weighed weekly.

Ptafr/ mice excessively gain weight irrespective
the type of diet

Behavior and metabolism assessment
Mouse metabolism was assessed using an Oxymax Lab Animal Monitoring System: CLAMS Comprehensive Lab Animal
Monitoring System (Columbus Instruments, Columbus, OH).
This system can continuously monitor food intake as well as

movement detection by interruption of triple axis infrared
beams. Interruption of a beam in any dimension accrues as
a single “count”. This system also continuously monitors
the volume of oxygen consumed and carbon dioxide
exhaled, which can be used to calculate the energy content
of the foodstuff utilized by the mouse. Mice were placed in
individual isolator cages and allowed to acclimate to the
environmental chamber for two days prior to data collection. The data were collected over a two-day period after
acclimation.

Body composition
At the end of experiments, the mice were weighted and
anesthetized with Ketamine/Xylazine (100/10 mg/kg, IP
injection). The abdominal cavity was opened via middle
incision and then abdominopelvic fat was isolated from
gonadal organs, and its wet weight measured. Liver was
isolated from surrounding tissue, all visible ligaments and
vessels were removed, and then the wet weight was
immediately measured. Data are presented as ratio of the
weight of abdominopelvic fat or liver to the body weight.

Statistical analysis

PAF is a potent inflammatory mediator,5 but PTAFR also
participates in non-inflammatory events. PAF modulates
complex physiologic events including blood pressure regulation,11 matrix production by renal tubulointerstitial
epithelial cells,12 vascular permeability in kidney,13 and
reproduction.4 A western diet (WD) induces chronic and low
level of inflammation,14,15 so to determine if potential dietmediated inflammation contributes to Ptafr-null-mediated
gain of body weight, we fed the WT and Pafr/ mice with
control diet (CD) or WD and body weight were monitored
continually up to 8 weeks. The study was initiated in 8week-old mice as at this moment there is no difference in
body weight was found between the two strains. The body
weight of the 8-week-old WT mice ingesting CD increased
linearly and reached a final weight of approximately 27 g
after 8 weeks feeding period (Fig. 1A), and gain about 4 g
body weight (Fig. 1B). As predicted, when WT mice were
fed WD, they gained weight at a greater rate than that of
CD-fed mice (Fig. 1A), and the difference became significant from week two of the trial, and increased over time
without achieving a constant value. Ultimately, these WDfed WT mice gained almost 10 g of weight over the eight
weeks feeding period (Fig. 1B). Ptafr/ mice ingesting CD
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Fig. 1 Ptafr deletion causes excessive weight gain. A & B. Body weight of 8-week old WT mice fed a chow diet (CD) or western
style high fat diet (TD.88137, WD) over the subsequent 8 weeks was monitored. A is showing the total body weight and B is the
differential gain in body weight over times. C & D. Body weight of 8-week-old Ptafr/ mice fed a CD or WD over the subsequent
8 weeks was measured. C is the total body weight and D is the differential gain in body weight. E & F. The differential gain in body
weight of WT and Ptafr/ mice in the 8-week feeding trial ingesting a CD (E) or WD (F) was compared. *p < 0.05, between groups
at each time point, n Z 8 in each group.

also significantly gained weight starting from the second
week onwards, which, in contrast to WT mice, continued
over the full 8 weeks feeding trial (Fig. 1C). As anticipated,
the weight gain by Ptafr/ mice ingesting a WD was also
robustly increased. The rates of weight change continued
throughout the trial in the Ptafr/ mice fed either a CD or
WD, although the rate of change was slower for the CD-fed
mice (Fig. 1D).
Comparison of weight gain over time between WT and
Ptafr/ animals revealed that Ptafr/ animals ingesting
either a CD (Fig. 1E) or WD (Fig. 1F) gained weight at a
significantly increased rate over WT animals. The largest
divergence, however, occurred in the CD feeding arm of the
experiment (Fig. 1E). WD consumption has been demonstrated inducing hypothalamic inflammation which contributes to obesity pathogenesis through the development
of central leptin and insulin resistance.14,15 There was no
difference in gain of weight in the late phase of WD fed WT
and Ptafr/ mice, suggesting that PTAFR does not
contribute to WD-induced inflammation, but rather PTAFR
plays a physiological role in controlling body weight.

Loss of PTAFR signaling did not promote aberrant
fat accumulation
To understand how PTAFR affects body weight, we determined whether the enhanced weight gain in Ptafr/ mice
is due to accumulation of adipose tissue. As anticipated, in
comparison to CD-fed animals, total abdominopelvic fat
became significantly more abundant when fed a WD in WT
mice (Fig. 2A) at both 8 and 12 weeks, although the
abdominopelvic fat did not significantly increase in mice
fed the CD over this time (p Z 0.28). However, the ratio of
abdominopelvic fat mass to total body weight was nearly
equivalent between Ptafr/ and WT mice fed a CD for
both 8 and 12 weeks (Fig. 2B). The total liver weight also
was comparable between the Ptafr/ and WT mice
feeding a CD for 12 weeks (Fig. 2C). This outcome implies
that adiposity alone does not account for the increased
body weight of Ptafr/ mice and that this tissue grows in
proportion with body size in animals lacking the PTAFR. This
phenotype differs from weight gain through adiposity reported before.9
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Fig. 2 WT and Ptafr/ mice have similar accumulation of adipose tissue under dietary trail. A. Eight-week old WT mice were fed
with a CD or WD for 8 or 12 weeks and then abdominopelvic fat was isolated and wet weight was measured. Data were presented as
ratio of fat mass to body weight. B & C. Eight-week old WT and Ptafr/ mice were fed with a CD for 8 and 12 weeks, and
abdominopelvic fat mass (B) and liver weight (C) were measured. n Z 3 in the WT groups, and n Z 3 at 8 weeks, n Z 2 at 12 weeks
in the Ptafr/ groups.

Ptafr deletion altered behavior, not energy
metabolism
To determine if PAF and its receptor play a role in energy
metabolism and thus control body weight, we used a CLAMS

animal monitoring system to quantify O2 consumption and
CO2 production as a measure of metabolism and energy
production from the ingested foodstuff. We examined mice
ingesting the CD since this diet generated the largest difference in body weight between the strains. We found a

Fig. 3 Ptafr deletion alters feeding and movement behaviors, but not energy metabolism monitored in a Comprehensive Lab
Animal Monitoring System (CLAMS). Eight-week old WT and Ptafr/ mice with same body weight ingesting a CD were monitored for
2 days after a 2 day acclimation period and the following data were harvested. A. The respiratory exchange rate (RER). B.
Accumulated food consumption over 24 h by individual WT and Ptafr/ animals. C. Ambulatory movement detected by interruption of an infrared beam in three dimensions over the stated interval. n Z 3, *p < 0.05; #p < 0.01 Ptafr/ vs. WT mice. D.
Rearing behavior monitored simultaneously as mentioned in panel C.
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Fig. 4 Gene Expression Omnibus (GEO) analysis of PTAFR expression. A. PTAFR expression in the white and brown adipose tissue
was compared based on the data extracted from GDS2813/1427872_at/Ptafr). B. PTAFR expression in omental adipose tissue in
normal and obese children was compared based on data extracted from the GDS3688/211661_x_at/PTAFR. One-tail t test were
used for the analysis.

diurnal variation in the respiratory quotient that was
maximal during the dark period in both WT and Ptafr/
mice (Fig. 3A). The patterns of the respiratory exchange
ratios overlaid one another, showing that there was no
significant difference in energy expenditure between the
two mouse strains. These data suggest that loss of Ptafr did
not affect dietary fat or carbohydrate metabolism.
The food weight was also monitored over the trail. The
CLAMS system tracks both food removed from the sensor as
well as food and the debris not ingested by the mice. Data
would have been less accurate when food intake was
measured weekly without specifically accounting for food
waste. We found that Ptafr/ mice ingested approximately 25% more diet than the WT mice over the two days
of metabolic analysis (Fig. 3B). This difference in accumulated food intake was highly significant (p Z 0.003), suggesting that PTAFR modifies food intake behavior.
Interestingly, when animal activities were monitored,
we found a pattern of lateral diurnal movement of WT and
Ptafr/ mice that was maximal during the dark cycle from
6 pm to 6 am (Fig. 3C). Notably, however, the activity of the
Ptafr/ mice was significantly less during the dark cycle of
each night than that of WT mice, with just as half as many
lateral beam disruptions by the Ptafr/ mice did. In
contrast, the number of rearing motions did not differ between the two strains (Fig. 3D). Rearing behavior is one
measure of interest in the novelty of the environment and
vigilance, suggesting that these two strains have similar
level of anxiety. In addition, these metabolic data were
harvested from 8-week-old mice and at this moment the
weight was not different between strains, indicating that
less movement of the Ptafr/ mice was not related to its
weight. We thus conclude that Ptafr/ mice were less
active, but also prone to ingest larger amounts of food.
Our findings are supported by several gene expression
studies. It has been indicated that obesity-resistant rats
have more PTAFR expression in liver (GEO profiles,
GDS3677/rn1900/Ptafr). A previous report indicated that
the anti-obesity effect of PTAFR results from altered
function of brown adipose.9 However, PTAFR expression is

significantly lower in the brown adipose tissue than in the
white adipose tissue (Fig. 4A) (GDS2813/1427872_at/
Ptafr),16 suggesting that PTAFR may function more on white
adipose tissue. This hypothesis is supported by another
gene expression experiment, in which expression of PTAFR
in omental adipose tissue, a white adipose, was dramatically reduced in obese children (GDS3688/211661_x_at/
PTAFR) (Fig. 4B).
PTAFR is expressed by, and functions in, the central
nervous system. PTAFR signaling increases kinase cascades
in the hippocampus,17 reduces activity of inhibitory GABA
neurons,18 and signals neuronal migration19 and death20 in
neurons and microglia. PAF orchestrates complex responses
in brain, contributes to long-term potentiation in the somatosensory cortex,21 learning22 and memory.23 PTAFR thus
possesses the capacity to regulate behavior through actions
in the central nervous system. However, more detailed
studies are necessary to clarify how PTAFR affects lifestyles
as well as its relationship to the obesity. Our novel findings
provide conceptual insights to control obesity, especially in
child and young adults, through regulating PTAFR mediated
life behavior modifications.

Conflicts of interest
All authors have none to declare.

Acknowledgments
We thank Drs. Takao Shimizu (University of Tokyo) and
Jeffrey Travers (University of Indiana) for providing the
Ptafr/ mice. We appreciate the advice of Mark Brown,
from the Department of Cellular & Molecular Medicine, and
the aid provided by Jazmine Danner and Ofer Reizes of the
Rodent Behavioral core facility of the Lerner Research
Institute. This work was supported by National Institute on
Alcohol Abuse and Alcoholism (NIAAA) 017748.

260

References
1. Kalin S, Heppner FL, Bechmann I, Prinz M, Tschop MH, Yi CX.
Hypothalamic innate immune reaction in obesity. Nat Rev
Endocrinol. 2015;11:339e351.
2. Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating
factor. J Biol Chem. 1990;265:17381e17384.
3. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor.
J Biochem. 2002;131:773e779.
4. Ishii S, Nagase T, Shimizu T. Platelet-activating factor receptor.
Prostagl Other Lipid Mediat. 2002;68e69:599e609.
5. Marathe GK, Davies SS, Harrison KA, et al. Inflammatory
platelet-activating factor-like phospholipids in oxidized low
density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem. 1999;274:28395e28404.
6. Shimizu T, Mutoh H, Kato S. Platelet-activating factor receptor.
Gene structure and tissue-specific regulation. Adv Exp Med
Biol. 1996;416:79e84.
7. McIntyre TM. Bioactive oxidatively truncated phospholipids in
inflammation and apoptosis: Formation, targets, and inactivation. Biochim Biophys Acta. 2012;1818:2456e2464.
8. Liu J, Li W, Chen R, McIntyre TM. Circulating biologically active
oxidized phospholipids show on-going and increased oxidative
stress in older male mice. Redox Biol. 2012;1:110e114.
9. Sugatani J, Sadamitsu S, Yamaguchi M, et al. Antiobese function of platelet-activating factor: increased adiposity in
platelet-activating factor receptor-deficient mice with age.
FASEB J. 2014;28:440e452.
10. Menezes-Garcia Z, Oliveira MC, Lima RL, et al. Lack of plateletactivating factor receptor protects mice against diet-induced
adipose inflammation and insulin-resistance despite fat pad
expansion. Obesity. 2014;22:663e672.
11. Malekin SI, Kotelevtsev SV, Gavrilova SA, et al. Long-term
normalization of blood pressure in SHR and 1-kidney 1-clip rats
by synthetic precursor of stable PAF analogue without systemic
effects in normotensive rats. Pathophysiology. 2011;18:
151e157.
12. Ruiz-Ortega M, Bustos C, Plaza JJ, Egido J. Overexpression of
extracellular matrix proteins in renal tubulointerstitial cells by
platelet-activating-factor stimulation. Nephrol Dial Transplant. 1998;13:886e892.

W. Li, T.M. McIntyre
13. Pirotzky E, Page C, Morley J, Bidault J, Benveniste J. Vascular
permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. Agents Actions. 1985;
16:17e18.
14. Thaler JP, Schwartz MW. Minireview: inflammation and obesity
pathogenesis: the hypothalamus heats up. Endocrinology.
2010;151:4109e4115.
15. Dixit VD. Adipose-immune interactions during obesity and
caloric restriction: reciprocal mechanisms regulating immunity
and health span. J Leukoc Biol. 2008;84:882e892.
16. Seale P, Kajimura S, Yang W, et al. Transcriptional control of
brown fat determination by PRDM16. Cell Metab. 2007;6:
38e54.
17. Moriguchi S, Shioda N, Yamamoto Y, Fukunaga K. Plateletactivating factor-induced synaptic facilitation is associated
with increased calcium/calmodulin-dependent protein kinase
II, protein kinase C and extracellular signal-regulated kinase
activities in the rat hippocampal CA1 region. Neuroscience.
2010;166:1158e1166.
18. Chen C, Bazan NG. Platelet-activating factor inhibits ionotropic GABA receptor activity in cultured hippocampal neurons. Neuroreport. 1999;10:3831e3835.
19. Tokuoka SM, Ishii S, Kawamura N, et al. Involvement of
platelet-activating factor and LIS1 in neuronal migration. Eur J
Neurosci. 2003;18:563e570.
20. Bate C, Kempster S, Williams A. Platelet-activating factor antagonists protect amyloid-beta damaged neurons from
microglia-mediated death. Neuropharmacology. 2006;51:
173e181.
21. Heusler P, Boehmer G. Platelet-activating factor contributes to
the induction of long-term potentiation in the rat somatosensory cortex in vitro. Brain Res. 2007;1135:85e91.
22. Row BW, Kheirandish L, Li RC, et al. Platelet-activating factor
receptor-deficient mice are protected from experimental
sleep apnea-induced learning deficits. J Neurochem. 2004;89:
189e196.
23. Chen C, Bazan NG. Lipid signaling: sleep, synaptic plasticity,
and neuroprotection. Prostagl Other Lipid Mediat. 2005;77:
65e76.

